AN2 Therapeutics announces funding extension for tuberculosis research collaboration with GSK

ANTX•2026-09-28

AN2 Therapeutics announced an extension of funding for its tuberculosis research collaboration with GSK. Gates Foundation funding supports advancement of boron-based LEURS inhibitors for TB treatment.

1. Funding extension

AN2 Therapeutics announced an extension of funding for its tuberculosis research collaboration with GSK. The company said Gates Foundation funding supports advancement of boron-based LEURS inhibitors for TB treatment.

AN2 Therapeutics announces funding extension for tuberculosis research collaboration with GSK

1. Funding extension

Related News

Deutsche Bank and IPID announce plans for strategic partnership

Safe Harbor Financial implements 1-for-12 reverse stock split on Sept. 30

Stocks fall as bond market flips to 'higher for longer' mode

Ainos enters VELDONA license deal with partner-funded development, secures $600,000 upfront fee

Sigma Lithium touts “Quintuple Zero” lithium oxide production at UN Climate Week New York